publication date: Nov. 7, 2014

David Nathan Receives Lifetime Achievement Award For Impact in Pediatric Cancer Research


DAVID NATHAN is the first recipient of the Boston Children’s Hospital Lifetime Impact Award at the hospital’s second annual Global Pediatric Innovation Summit.

Nathan is president emeritus of Dana-Farber Cancer Institute and physician-in-chief emeritus of Boston Children’s Hospital. The award recognizes a clinician or researcher who has devoted their entire career to accelerating innovation in pediatric medicine.

In nominating Nathan for the award, David Williams, chief of hematology/oncology at Boston Children’s and associate chairman of pediatric oncology at Dana-Farber, called his mentor a “proverbial ‘triple threat’” who “combined outstanding clinical care, research and teaching leadership,…while he also steered two major academic institutions to greater heights.”

Nathan’s research was instrumental in the creation of the first successful treatment for iron overload in thalassemia patients, prenatal diagnosis of thalassemia and sickle cell disease, and the drug hydroxyurea, now a mainstay for managing the disease’s painful effects for many patients. Nathan is also credited with enhancing the stature of both Boston Children’s and Dana-Farber as research and teaching institutions.


STEVEN FINKELSTEIN was appointed national chief science officer of 21st Century Oncology.

Finkelstein is national director of the Translational Research Consortium, the research arm of 21st Century Oncology, and an adjunct associate professor at the Translational Genomic Research Institute.

He has various leadership roles in the American Society of Clinical Oncology, the American Society for … Continue reading 40-42 The Cancer Letter In Brief

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.